A Study of YL242 in Subjects With Advanced Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor
In brief
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
Key facts
- Study ID
- NCT07197827
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
- People needed
- 424
- Starts
- 2025-09-22
- Expected to finish
- 2028-11-01
- Last updated by the study team
- 2025-12-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged ≥18 years.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Adequate organ and bone marrow function
- Tumor type:
- Part 1-3: Advanced/unresectable or metastatic solid malignant tumor; Have received at least one prior line of systemic anti-tumor therapy
- Part 4: locally advanced or metastatic non-sq NSCLC without AGA and HCC; Have not received any systemic anti-tumor therapy;
- Part 5: mCRC, have received at least one (5a) or one (5b) prior line of systemic anti-tumor therapy
- Part 6: advanced or metastatic HER2-negative G/GEJ; have received at least one (6a) or one (6b) prior line of systemic anti-tumor therapy
You may not qualify if…
- Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor
- Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases
- Clinically significant concomitant pulmonary disease
- A history of leptomeningeal carcinomatosis or carcinomatous meningitis
- Any illness, medical condition, organ system dysfunction, or social situation, including but not limited to mental illness or substance/alcohol abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, adversely affect the patient's ability to cooperate and participate in the study, or compromise the interpretation of study results
Where it is running
- AUS-102 — Darlinghurst, Victoria, Australia (enrolling)
- US-202 — Sarasota, Florida, United States (enrolling)
- US-206 — Grand Rapids, Michigan, United States (enrolling)
- US-205 — Nashville, Tennessee, United States (enrolling)
- CN-303 — Harbin, Heilongjiang, China (enrolling)
- CN-301 — Shanghai, Shanghai Municipality, China (enrolling)
- CN-302 — Hangzhou, Zhejiang, China (enrolling)
- AUS-105 — Nedlands, Western Australia, Australia
- AUS-101 — Liverpool, New South Wales, Australia
- US-204 — Boston, Massachusetts, United States
- US-203 — Houston, Texas, United States
- US-207 — San Antonio, Texas, United States
- US-201 — New Haven, Connecticut, United States
- AUS-104 — Fitzroy, Victoria, Australia
- AUS-103 — Heidelberg, Victoria, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.